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AbstrAct
The human papillomavirus (HPV) can cause a range of cancers as well as genital warts and recurrent respira-
tory papillomatosis in men and women. Most cases can be prevented by vaccination in adolescence. Many
countries vaccinate girls and an increasing number, although still a minority, vaccinate both boys and girls.
The case for vaccinating boys is based on arguments of public health, equity, ethics, and cost-effectiveness.
The selective vaccination of females does not protect males sufficiently and provides no protection at all for
men who have sex with men. In the United Kingdom (UK), the government’s vaccination advisory com-
mittee (Joint Committee on Vaccination and Immunisation [JCVI]) began to consider whether boys should
be vaccinated as well as girls in 2013 and made clear in draft statements that it considered this not to be
cost-effective. A campaign group, HPV Action, was established to advocate gender-neutral vaccination. This
group became a coalition of over 50 organisations and used evidence-based arguments, political advocacy
and media campaigning to make its case. One of its members initiated legal action against the government
on the grounds of sex discrimination. In July 2018, the government agreed that boys in the UK should be
vaccinated. The lessons for other campaigns in the men’s and public health fields include: be prepared for
the long haul, focus on clear and specific goals, build alliances, align the objectives with existing policies,
make a financial case for a change of policy, and use all legitimate means to exert pressure.
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In July 2018, the United Kingdom (UK) govern-
ment’s vaccination advisory committee (Joint Com-
mittee on Vaccination and Immunisation [JCVI]) 
recommended that the national human papillomavirus 
(HPV) vaccination programme should be extended 
to include adolescent boys. This decision was made 
after five years’ deliberation by JCVI. For most of 
that time, JCVI indicated that it was highly sceptical 
of the case for vaccinating boys. It is worth reflect-
ing on how and why JCVI changed its position in the 
final few months and what the lessons might be for 
other men’s and public health campaigns in the UK 
and elsewhere.
HumAn PAPillomAvirus
HPV is the name for a group of viruses that affect 
the skin and moist membranes lining the body.1 Vul-
nerable areas for HPV infection in males include the 
penis, anus, mouth and throat. In women, as well as the 
anus, mouth and throat, other susceptible areas are the 
cervix, vagina and vulva. There are around 200 types 
of HPV.2 Most are harmless, but persistent infection 
with some types can cause cancer or genital warts.
The main high-risk types of HPV are HPV 16 
and 18. These, and a few other, types can cause can-
cer. Genital warts are caused by HPV 6 and 11. The 
cancer-causing and wart-causing types are different, 
meaning that genital warts are not a precursor of can-
cer. HPV infection is very common and is spread by 
sexual and skin-to-skin contact. Condoms reduce the 
risk of infection but do not eliminate it because HPV 
can infect areas not protected by a condom.3  Some 
studies suggest that deep kissing spreads HPV but 
this has not been definitely proven.4 High-risk HPV 
types cannot be caught from toilet seats, hugging, 
holding hands, swimming pools or hot tubs or sharing 
food or cutlery.5
Nearly all sexually active people acquire HPV at 
some point in their lives: about 85% of women and 
91% of men will be infected.6 Because the infection 
is so common, many people are infected shortly after 
becoming sexually active. Someone who has had only 
one sexual partner can get HPV although people who 
have many partners, or who have sex with someone 
who has had many partners, are more at risk. There 
is a 50–80% chance of HPV transmission following 
unprotected sexual intercourse with someone with a
current HPV infection.7
There are important differences in the epidemiol-
ogy of HPV infection between men and women. For
example, HPV transmission from females to males is
higher (12.3%) than from males to females (7.3%).8
HPV infection rates also seem to stay constant in men,
independent of age, whereas in women, who have a
better immune response, HPV prevalence is highest
during 18–24 years of age and then decreases until
middle age, after which it generally remains steady.9
Most people with HPV are unaware that they are
infected and never develop a health problem as a result.
HPV usually clears on its own: approximately 70%
of men clear an HPV infection within 12 months.10
Having HPV does not therefore mean someone will
automatically develop cancer or genital warts. But HPV
infection can persist in some people, causing health
problems sometimes years later. It is not possible to
predict which people with HPV will go to develop
health problems but people with compromised im-
mune systems are thought to be more at risk as are
smokers. People with HIV/AIDS are among those at
greater risk.11
HPv-relAted diseAses
HPV is believed to cause 5% of all cancers world-
wide.12  A study of the impact of HPV on cancers in
32 European countries suggested that over 53,000
cancer cases a year are caused by high-risk HPV
types. About 80% of these cases occur in women
and 20% in men.13 Cervical cancer represents the
highest burden (31,130 cases), followed by head and
neck cancer (1,396 cases in women, 5,834 cases in
men), anal cancer (3,834 in women and 2,303 cases
in men), vulvar cancer (1,466 cases), vaginal cancer
(1,360 cases), and penile cancer (1,113 cases).
Head and Neck Cancers
HPV causes cancer in different parts of the head
and neck, especially the oropharynx. (The oropharynx
includes the back third of the tongue, the soft area at
the back of the roof of the mouth, the tonsils and the
back wall of the throat.) Over 70% of oropharyngeal
cancer cases are caused by HPV.14 This cancer mostly
affects men– they are twice as likely to be affected
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as women. Mouth and throat cancers caused by HPV
have become far more common over the past 30
years, a trend that is expected to continue over the
next 20 years.15
Anal Cancer
HPV causes the vast majority (90%) of anal cancer
cases.16 This cancer is relatively rare and is about twice
as common in women. But the number of cases in men
is expected to more than double in the period 1993 to
2035.17 In men, anal cancer is much more common
in men who have sex with other men; in fact, rates of
anal cancer are 17 times higher in men who have sex
with men compared to heterosexual men.18
Penile Cancer
HPV infection causes about two thirds (63%) of
penile cancer cases.19 This cancer is relatively rare in
the UK, but is becoming more common with almost
25% more cases now being diagnosed each year than
in the early 1990s.20
Genital Warts
Infection with HPV types 6 and 11 can cause genital
warts, the second most common sexually transmitted
infection. In men, warts can develop on the penis,
scrotum, the upper thighs, and on or inside the anus.
Both men and women are affected but the problem is
much more common in men and particularly in men
who have sex with men. A review of the international
evidence found that, among males, prevalence of genital
warts ranged from 0.16% to 0.20%; among females,
prevalence ranged between 0.13% and 0.16%.21 Men
experience high rates of recurrent genital warts: one
study found that 44% had one or more subsequent
genital wart events detected, 22% had two subsequent
events, 11% had three subsequent events, and 7% had
four or more subsequent events.22
Recurrent Respiratory Papillomatosis
HPV types 6 and 11 can also cause recurrent re-
spiratory papillomatosis (RRP).23 People with RRP
have wart-like growths on their airways caused by
HPV which can seriously affect breathing. RRP affects
both children and adults. Children are infected while
still in the womb or at birth. Males and females are
about equally affected. RRP is rare but can be very
distressing and is often difficult to treat.
Other Diseases
Some studies have suggested that HPV infection 
is associated with prostate cancer and some types of 
lung and breast cancers. A meta-analysis of 30 stud-
ies suggested that men who tested positive for HPV 
type 16 had a 37% greater risk of developing prostate 
cancer.24 An international pooled analysis found that 
comparisons between tumour and normal lung tissue 
showed that HPV was almost four times more likely 
to be present in lung cancer rather than normal lung 
tissue.25 There has also been a recent suggestion of 
a link between HPV infection and cardiovascular 
disease.26 Most scientists consider these links to be 
unproven, however, and HPV vaccination is not con-
sidered to be a means of preventing prostate, lung or 
breast cancers or heart disease.
HPv vAccinAtion
HPV vaccination offers a very safe and very reli-
able protection against HPV infection but it is not 
a treatment for an existing infection. It is normally 
administered to adolescents before they become sexu-
ally active and at risk of exposure to the virus. There 
are three vaccine products available: Cervarix (which 
protects against HPV types 16 and 18), Gardasil (for 
HPV types 6, 11, 16 and 18) and Gardasil-9 (for HPV 
6, 11, 16, 18 and five other oncogenic HPV types). 
Gardasil is currently the market leader globally; 
Cervarix accounts for about one-fifth of the market.27 
When offered to adolescents, two vaccine doses are 
required for maximum protection. It is possible that 
current research will in the near future confirm that 
just one dose is sufficient.28
HPV vaccination for girls was initially introduced 
in 2006 with the USA being the first country to do so. 
By March 2017, 71 countries (37%) had introduced 
a female HPV vaccination programme.29 This has 
been on an inequitable basis however: only 1% of 
vaccinated females have been from low-income or 
lower-middle-income countries. Many more women 
from high-income and upper-middle-income countries 
have been vaccinated against HPV while populations 
with the highest incidence and mortality of HPV-
related disease have remained largely unprotected.30
Males have not been included in HPV vaccination 
programmes in most countries. Data collected by 
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HPV Action suggests that, by early 2019, just over 
30 countries have either decided to vaccinate boys or 
actively plan to do so. These countries are: 
Antigua and Barbuda
Argentina
Australia
Austria
Bahamas
Barbados
Bermuda
Brazil
Canada
Croatia
Czech Republic
Denmark
Germany
Gibraltar
Guam
Guyana
Ireland
Israel
Italy
Liechtenstein
New Zealand
Norway
Panama
Portugal
Puerto Rico
Serbia
Slovakia
St Lucia
Switzerland
Trinidad and Tobago
Turkmenistan
United Kingdom
United States of America
All the above countries are in the high- or upper-
middle-income brackets, according to World Bank 
criteria.31 
tHe cAse for vAccinAting boys
Although the number of male cancer cases caused 
by HPV infection is lower than the number for females, 
the virus still causes significant levels of disease in 
males. Because optimal health is considered to be 
a fundamental human right, there is a very strong 
ethical argument for vaccinating both sexes.32 This is 
reinforced by arguments based in equity and equality 
which suggest that not vaccinating boys constitutes 
sex discrimination.
It has been suggested that in countries where vac-
cination rates in girls are sufficiently high (normally 
meaning ≥80%), boys are protected against HPV 
infection because, clearly, they cannot acquire it from 
vaccinated females.33 The protective (‘herd’) effect of 
the selective vaccination of adolescent girls against 
HPV implies a high probability that one of the two 
sexual partners is immunised, hence preventing the 
other from acquiring the virus. 
This argument is highly problematic, however. 
The dynamic transmission models used to inform 
immunisation policy should include consideration
of sexual behaviours and population mixing in order
to demonstrate an ecological (‘real world’) validity,
whereby the scenarios modelled remain faithful to the
real-life social and cultural context.34 An assumption
of herd protection by means of female vaccination
first and foremost ignores the fact that men who have
sex with men remain totally unprotected.35 There is
also growing evidence that an increasing number of
men who identify as heterosexual are sexually ‘fluid’
(i.e. have same-sex relationships)36 and embracing a
significantly more inclusive, tactile and emotionally
diverse approach to their relationships with other
men37 which may well increase the risk of male-male
HPV transmission.
A few countries, including the UK, have intro-
duced vaccination programmes specifically for men
who have sex with men. While these may benefit
some individual men, the main drawback with such
programmes is that men are likely to have acquired
HPV before they are offered the vaccine and, in any
event, many men who have sex with men will not be
reached by these programmes.38 The most effective
way to prevent HPV infection in men who have sex
with men is to vaccinate all boys before they become
sexually active.
Men also have sexual contact with women who
have not been vaccinated. This may be in their own
country – even if 80% of girls there are vaccinated,
that means that, on average, one in five new sexual
contacts will be with someone who has not been
vaccinated (and that assumes that the contact is with
a woman in an age-group for which vaccination was
available). In Europe, just 4% of all women are esti-
mated to have been vaccinated; in northern Europe,
the best-performing region, the figure rises to 8%.
Vaccination uptake in girls varies significantly across
European Union (EU) countries. Few meet the 
widely-accepted target of 80% coverage.39 In 
western and southern Europe, about one-third of 
girls in the targeted populations are estimated to have 
completed the full course of vaccina-tions. In eastern 
Europe, the proportion is one-fifth. In northern 
Europe, the best-performing region, about two-thirds 
of girls have been vaccinated. Vaccination rates can 
also vary widely within countries. The UK has a 
high overall vaccination rate (about 83%) but,
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at the local level, uptake in girls varies from under 
50% to 95%.40 Vaccinating boys helps to protect 
unvaccinated women.
Men may also have sex with women from other 
countries where there may be no HPV vaccination 
programme or where there is a programme with 
relatively low uptake. The growth of global tourism 
(including sex tourism), business travel and migra-
tion means that increasing numbers of men are at risk 
from unvaccinated women. Data from the UK shows 
that around 10% of men report forming a new sexual 
partnership while overseas in the past five years.41 The 
proportion among younger men is far higher: 13% of 
16–24 year olds and 15% of 25–34 year olds. 
There is evidence that vaccinating boys is cost-
effective42 although this is a highly-contested issue. 
Essentially, cost-effectiveness means that the outcomes 
of an intervention are worth the investment in terms 
of the savings in treatment and care that accrue when 
compared to investing in other health services. A study 
of the cost-benefits in Finland found that vaccinating 
girls eventually leads to annual savings of EUR 11.2 
million in the treatment of HPV-related cancers and 
that vaccinating boys would produce additional annual 
savings amounting to EUR 4.1 million.43 Another 
study found that, in Canada, vaccinating boys could 
potentially save between CAD 8 and CAD 28 million 
in the treatment of oropharyngeal cancers alone.44
It has been suggested that, rather than investing in 
vaccination for males, the focus should be on improv-
ing uptake in females.45 While higher levels of female 
uptake do protect some males, even 90% female uptake 
still leaves men at risk, not least men who have sex 
with men. It is also unrealistic to expect significant 
improvements in female uptake in many countries in 
the short-term; this has led to calls for gender-neutral 
vaccination in Africa and for Gavi, the Vaccine Alli-
ance, which currently provides subsidised female-only 
HPV vaccines to eligible African countries, to extend 
the subsidy to gender-neutral vaccination.46
AdvocAting HPv vAccinAtion for 
boys in tHe uK
The decision to vaccinate boys in the UK was not 
made, as it should have been, following an objec-
tive and independent assessment of the evidence of 
cost-effectiveness by an official advisory body. The 
JCVI’s decision that the HPV vaccination programme 
should be extended to boys came after a sustained ad-
vocacy campaign led by HPV Action, a partnership of 
(ultimately) 51 professional and patient organisations.
HPV vaccination for girls aged 12/13 years began 
in the UK in 2008. At the same time, a short-term 
catch-up programme for girls aged up to 18 years was 
introduced. The programme was delivered in schools 
and has achieved relatively high rates of uptake. The 
latest 2016/17 figure for the UK is 85% although this 
masks significant local variations.47
JCVI began an assessment of whether boys should 
also be vaccinated in 2013 and, at that time, planned 
to announce a decision in 2015. In 2013, representa-
tives of several organisations with a particular interest 
in HPV-related diseases (chiefly the Throat Cancer 
Foundation and the HPV and Anal Cancer Foundation 
charities) decided to establish an advocacy organisation, 
HPV Action, to make the case for the vaccination of 
boys. Peter Baker, an independent consultant in men’s 
health who had been Chief Executive at the Men’s 
Health Forum (Great Britain) and was now Director 
of Global Action on Men’s Health, was invited to 
become campaign director on a freelance basis. 
The choice of a leading advocate from a background 
in gender and health inequalities who was already 
well-connected with a wide range of potential HPV 
Action members as well as key external stakehold-
ers was undoubtedly helpful to the campaign. The 
appointment of a freelance contractor rather than 
using the more conventional option of a public affairs 
agency was also very cost-effective. The total cost of 
the campaign over five years was an estimated GBP 
75,000.00, including in-kind contributions from mem-
bers. This is a relatively small amount for campaigns 
of this kind.
HPV Action’s advocacy campaign was financed 
almost entirely by voluntary contributions from its own 
members with a small amount of extra income from 
individual donations and a commercial organisation 
without a direct financial interest in HPV vaccination. 
Not all members made a financial contribution and a 
few (the Oral Cancer Foundation, the Throat Cancer 
Foundation and the HPV and Anal Cancer Founda-
tion) provided most of the support. Towards the end 
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of the campaign, Oral Health Foundation accepted an
educational grant from a vaccine manufacturer (MSD)
to enable HPV Action to produce online educational
material on vaccination for boys and men. This grant
was strictly ring-fenced and was not used to support
the advocacy campaign. Some members also provided
pro bono support such as meeting rooms, design and
publication. A PR company working for the HPV and
Anal Cancer Foundation, Street and Co, provided
media support.
HPV Action began to recruit members and, by the
end of 2013, had 22. A year later, it had 36, and this
number continued to steadily increase. The members
came from a range of backgrounds, including men’s
health, gay men’s health, sexual health, cancer, oral
health and public health. They ranged from the small
to the large, from local to national, and from low- to
high-profile. The level of participation by member
organisations varied widely but all contributed to the
overall visibility and influence of the campaign. HPV
Action also benefitted from the active participation
of Professor Giampiero Favato, a health economist
based at Kingston University in the UK who had
previously advised the Italian government on gender-
neutral vaccination.
The campaign did not constitute itself as a formal
organisation. It did not register as a charity or a com-
pany; it remained a network throughout. HPV Action’s
finances were managed by one of its members, the
Oral Health Foundation, which was also responsible
for managing the work of the campaign director and 
for paying his fees. Strategic decisions were taken by 
regular meetings open to all members and a small
number of members was responsible for executive
decision-making. Members were kept informed through
regular eBulletin updates. Terms of reference were
agreed by members to ensure good governance and
enable relatively fast decision-making and responses
to external events.
The campaign was four-pronged48 in its approach.
The first element was to influence professional opinion,
including that of JCVI members. This was primarily
achieved through evidence-based articles in profes-
sional journals for school nurses, dentists, public health
specialists and others. There were also occasional
papers in scientific and medical journals49–56 as well
as presentations to conferences and seminars. HPV 
Action also had direct contact with JCVI by means of 
submissions to its consultations, direct correspondence 
and meetings with the officials who were supporting 
its work, chiefly based at Public Health England. It is 
difficult to assess objectively the impact of this activ-
ity but, by 2018, there seemed to be a professional 
consensus that gender-neutral vaccination would be 
beneficial to public health. 
HPV Action consistently argued that JCVI’s ap-
proach to assessing cost-effectiveness was flawed. Public 
Health England, which undertook cost-effectiveness 
modelling for JCVI, admitted in a paper published 
after the decision was made that the outcome of any 
model is strongly dependent on the variance of the 
inputs chosen to inform its algorithm.57 Models based 
on deterministic inputs, such as the ones available to 
JCVI, might be affected by a different degree of eco-
logical bias, which implies an inability to reflect the 
natural demographic and behavioural trends in their 
outcomes and, consequently, to accurately inform 
public healthcare policy. In particular, ecological bias 
has the effect of over-estimating the preference-based 
outcomes of selective immunisation. A relatively small 
(15–20%) over-estimation of the herd immunity gained 
with selective immunisation programmes could induce 
a significant error in the estimate of cost-effectiveness 
of universal immunisation by inflating its incremental 
cost-effectiveness ratio (ICER) beyond the accept-
ability threshold.58
HPV Action successfully demonstrated that the 
model originally used by JCVI seriously under-
estimated the proportion of cancer cases in men 
caused by HPV. The campaign also cast doubt on 
the validity of using dated, pre-Tinder assumptions 
of sexual behaviour (there is evidence that dating 
apps constitute an emerging sexual risk factor59 and 
that high-risk sexual behaviours, notably anal sex, 
have become increasingly and rapidly prevalent60) 
and highlighted the omission from the modelling of 
significant areas of cost, such as the cost of morbidity 
and mortality to employers.
Because the arguments about cost-effectiveness 
are complex and difficult to understand by people 
without a background in health economics, HPV 
Action produced a straightforward estimate of the 
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costs of introducing gender-neutral vaccination. Using
publicly-available data about the cost of the vaccine
in Italy combined with information about the cost of
vaccine delivery in the UK, the campaign calculated
that the annual cost of adding boys to the HPV 
vaccination program in the UK would be in the 
region of GBP 20-22 million.61 This was then 
compared to the significantly greater costs of 
treating HPV-related diseases.
Significant emphasis was also placed on the ethical
and equity arguments as well as the potential public
health outcomes. The risk of the potential impact
of a fall in vaccine confidence on girls’ uptake was
also highlighted; HPV Action cited the recent major
downturns in vaccination in Denmark, Japan and
Ireland which followed media coverage of some par-
ents’ vaccine safety concerns. (There is no credible
scientific evidence of any negative long-term impact
of HPV vaccination.)62
The contribution that gender-neutral vaccination
could make to implementing other areas of policy
were emphasised. The UK government had made a
strong commitment to tackling health inequalities,
for example, and HPV Action argued that vaccinat-
ing boys would help to reduce the gap in outcomes
between men and women. It also suggested that it was
unfair to expect girls to bear sole responsibility for
tackling this sexually transmitted infection through
the burden of vaccination.
The second element was political. Significant ef-
forts were made to engage politicians from all political
parties and to exert pressure on government ministers
through correspondence and formal questioning and
debates in parliament. Of particular importance was
a parliamentary debate on gender-neutral vaccination
held in May 2018, a few weeks before the meeting
where JCVI decided to recommend gender-neutral
vaccination. The debate was initiated by a senior
MP from the governing Conservative Party and the
case was supported by other Conservative MPs as
well as MPs from the Labour, Scottish Nationalist
and Democratic Unionist parties. During that 
debate, the public health minister, Steve Brine MP, 
conceded that equality issues needed to be 
considered alongside cost-effectiveness.63
The third element involved the media. HPV Ac-
tion succeeded in gaining sustained media coverage
throughout its campaign. Stories were developed 
which created new angles, such as a report on the 
views of Nobel Prize winner Professor Harald zur 
Hausen (the scientist who discovered the link between 
HPV and cervical cancer and who strongly supports 
boys’ vaccination) and a national survey of dentists 
and doctors. Organised with the help of the British 
Dental Association, Faculty of General Dental Prac-
tice and BMA (the main trade union for doctors in 
the UK), the survey found that 95% of respondents 
thought boys should be vaccinated. Of most signifi-
cance was the support of a major national newspaper, 
The Mail on Sunday (MoS), throughout the first six 
months of 2018. The MoS ran a series of hard-hitting 
articles, often based on the case-studies of people 
with HPV-related cancers, which made the case for 
gender-neutral vaccination. The MoS is the second 
best-selling Sunday newspaper in the UK and has a 
readership demographic that makes it influential with 
governments, especially Conservative governments.
The final element concerned the threat of legal 
action. One of HPV Action’s members, the Throat 
Cancer Foundation, initiated judicial review proceed-
ings against the Department of Health and Social Care 
and the JCVI on the grounds that not vaccinating 
boys was direct sex discrimination. The Foundation 
raised sufficient funds through a crowdfunding site 
and a letter was sent in early 2018 to the potential 
defendants from a leading law firm, Leigh Day, with 
extensive experience in human rights and equality 
cases. This case did not proceed to court because the 
government decided to vaccinate boys before that step 
became necessary.
Many organisations and individuals not under the 
HPV Action umbrella also played an important role in 
the campaign. The BMA adopted a policy supporting 
HPV vaccination for boys in 2014. Professor Margaret 
Stanley of Cambridge University, now president of 
the International Papillomavirus Society, and Profes-
sor Chris Nutting, Consultant Clinical Oncologist at 
the Royal Marsden Hospital in London, were primus 
inter pares among the many individual and influential 
clinicians and academics who helped to make the case 
for gender-neutral vaccination. 
The campaign was not without its downsides. 
HPV Action was unable to engage the general public, 
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especially parents who could have lobbied their MPs, 
primarily because of a lack of resources. At times, the 
campaign had very limited funds and the financial 
burden was borne by a relatively small number of 
member organisations, sometimes causing tension 
within the membership. The lack of funds also con-
strained HPV Action’s activities. An online petition, 
begun in 2013, was sidelined because HPV Action 
was unable to promote it sufficiently widely. Some 
significant organisations in the cancer and medical 
field, whose support would have been helpful, chose 
not to support the call to vaccinate boys until the 
decision was actually announced. 
lessons for otHer men’s And Public 
HeAltH cAmPAigns
The ultimate success of HPV Action’s campaign 
suggests some useful lessons for other campaigns 
in the men’s and public health fields. These include:
1. Be prepared for the long haul. Significant 
change is unlikely to be achieved quickly.
2. Focus on clear and specific goals rather than 
a diverse set of demands.
3. Secure funding from sources that have no 
direct financial interest in the outcome of the 
campaign. 
4. Base campaigns on credible evidence rather 
than assertion. But do not overlook the power 
of personal stories (e.g. of HPV-related cancer) 
and of appeals to people’s sense of fairness.
5. Make a financial case for a change of policy. 
Many politicians and policymakers are influ-
enced by proposals that potentially reduce 
healthcare costs.
6. Build alliances. Support from other reputable 
organisations and individuals can be invaluable.
7. Engage politicians, ideally from more than 
one party, including the governing party. 
Politicians have a unique public platform and 
can also raise issues behind-the-scenes with 
government ministers.
8. Seek media coverage. This can be a way of 
recruiting further support, especially from the 
general public, and of exerting greater pressure 
on politicians and policymakers.
9. Align the campaign with existing policies to
show how the desired objective would have
wider benefits.
10. Use all legitimate means to exert pressure,
including legal action if appropriate.
11. Appoint highly-motivated individuals to leader-
ship positions within the campaign.
12. Conduct the campaign in a way that is respect-
ful while also challenging manner and avoid
divisiveness, for example by adopting the
fallacious ‘men’s rights’ view that the health
of men and boys is being ignored because of a
feminist conspiracy to favour women and girls.
finAl comments
When the JCVI’s recommendation to vaccinate
boys was made in July 2018, it still came as a surprise
to HPV Action and its members. It had looked as if
JCVI would remain wedded to its earlier clearly-stated
position that gender-neutral vaccination was not cost-
effective. Its eventual support for universal vaccination
against HPV was, without doubt, directly attributable
to the campaign waged by HPV Action and its allies.
Because JCVI is regarded internationally as one of
the most rigorous and reputable vaccination advisory
bodies, its decision is likely to have a significant impact
on other countries’ HPV vaccination policies. The UK’s
decision should make it easier for advocates to make
the case for gender-neutral HPV vaccination elsewhere.
A new organisation, HPV Action Europe, is 
likely to launch in 2019 with the primary aim of 
seeking gender-neutral vaccination throughout 
Europe, initially in the EU and then throughout the
53 countries in the WHO Europe region. Several of
HPV Action’s members, and also the campaign direc-
tor, would be actively involved in the new 
organisation and the advocacy work in Europe will 
be able to draw heavily on the experience gained 
during the UK campaign.
The vaccination of boys in the UK is due to begin
in September 2019.
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